Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background & Aims Infection with the gastric mucosal pathogen H. pylori is the strongest identified risk factor for distal gastric cancer. These bacteria colonize a significant part of the world’s population. We investigated the molecular mechanisms of p53 regulation in H. pylori-infected cells. Methods Mongolian gerbils were challenged with H. pylori and their gastric tissues were analyzed by immunohistochemistry and immunoblotting with p53 antibodies. Gastric epithelial cells were co-cultured with H. pylori and the regulation of p53 was assessed by real-time PCR, immunoblotting, immunofluorescence, and cell survival assays. shRNA and dominant-negative mutants were used to inhibit activities of HDM2 and AKT. Results We found that in addition to previously reported up-regulation of p53, H. pylori can also negatively regulate p53 by increasing ubiquitination and proteasomal degradation via activation of the serine/threonine kinase AKT, which phosphorylates and activates the ubiquitin ligase HDM2. These effects were mediated by the bacterial virulence factor, CagA; ectopic expression of CagA in gastric epithelial cells increased phosphorylation of HDM2 along with the ubiquitination and proteasomal degradation of p53. The decrease in p53 levels increased survival of gastric epithelial cells that had sustained DNA damage. Conclusion H. pylori is able to inhibit the tumor suppressor p53. H. pylori activates AKT, resulting in phosphorylation and activation of HDM2 and subsequent degradation of p53 in gastric epithelial cells. H. pylori-induced dysregulation of p53 is a potential mechanism by which the microorganism increases the risk of gastric cancer in infected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Suzuki, M., Mimuro, H., Kiga, K., Fukumatsu, M., Ishijima, N., Morikawa, H., Nagai, S., Koyasu, S., Gilman, R. H., Kersulyte, D., et al. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.11.010 · Cited by 338
Cited by
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302084 · Cited by 2,266
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Helicobacter pylori-induced gastric inflammation and gastric cancer
Wang, F., Meng, W., Wang, B., & Qiao, L. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.08.016 · Cited by 793
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Takahashi-Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0339-5 · Cited by 299
HATAKEYAMA, M. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.013 · Cited by 261
Buti, L., Spooner, E., Van der Veen, A. G., Rappuoli, R., Covacci, A., & Ploegh, H. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106200108 · Cited by 253
“The link to the p53 pathway has been suggested in the context of B-cell lymphoma and epithelial cells, although a direct connection between CagA and p53 has not been shown (14, 40).”
BackgroundSpermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA
Chaturvedi, R., Asim, M., Romero–Gallo, J., Barry, D. P., Hoge, S., de Sablet, T., Delgado, A. G., Wroblewski, L. E., Piazuelo, M. B., Yan, F., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.045 · Cited by 208
Self-citationCollateral damage: Insights into bacterial mechanisms that predispose host cells to cancer
Gagnaire, A., Nadel, B., Raoult, D., Neefjes, J., & Gorvel, J.-P. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.171 · Cited by 189
P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
“This protein kinase phosphorylates the MDM-2 protein and activates it, enhancing its E3 ligase activity and inactivating p53 [22].”
BackgroundTargeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Jang, S. H., Lim, J. W., Morio, T., & Kim, H. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.010 · Cited by 62
Borozan, I., Zaidi, S. H., Harrison, T. A., Phipps, A. I., Zheng, J., Lee, S., Trinh, Q. M., Steinfelder, R. S., Adams, J., Banbury, B. L., et al. (2022) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0463 · Cited by 57
Said, S., & Ibrahim, W. (2025) · Cancer Management and Research · doi:10.2147/cmar.s405590 · Cited by 25
Metadata
- Authors
- Wei, J., Nagy, T. A., Vilgelm, A., Zaika, E., Ogden, S. R., Romero–Gallo, J., Piazuelo, M. B., Correa, P., Washington, M. K., El–Rifai, W., Peek, R. M., & Zaika, A.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 139
- Issue
- 4
- Pages
- 1333-1343.e4
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1977793644
- Cited by
- 190
- References
- 2
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.